Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (456)	12/23/2003 2:04:30 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

AGEN In spite of the announcement, the stock was not able to close above its December 1 H of 12.83 <g> NEW YORK--(BUSINESS WIRE)--Dec. 22, 2003-- Patient Accrual Target Sufficient Trial Design and Conduct Declared Sound No Safety Concerns Identified. Antigenics announced today that the Data Monitoring Committee (DMC) convened as scheduled for the interim analysis of a PIII trial of its Oncophage in the treatment of RCC. The DMC recommended that the trial proceed as planned and declared the design and conduct of the trial sound,and it raised no safety concerns. The trial,involves more than 650 patients. "We are most encouraged and pleased by the DMC's recommendations. Antigenics hopes to bring this treatment to RCC patients in the near future," said G.H. Armen,PhD, CEO of AGEN. The randomized, two-arm study is evaluating the effect of patients in the trial either receive nephrectomy followed by observation, or nephrectomy followed by Oncophage administered on an outpatient basis over the course of several weeks. Oncophage is derived from each individual's tumor, contains the 'antigenic fingerprint' of the patient's particular cancer and is intended to leave healthy tissue unaffected.It has been granted fast track and orphan drug designations from the FDA in both metastatic melanoma and RCC. siliconinvestor.com Bernard